291 related articles for article (PubMed ID: 18973782)
1. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants.
Braun LJ; Tyagi A; Perkins S; Carpenter J; Sylvester D; Guy M; Kristensen D; Chen D
Vaccine; 2009 Jan; 27(1):72-9. PubMed ID: 18973782
[TBL] [Abstract][Full Text] [Related]
2. A freeze-stable formulation for DTwP and DTaP vaccines.
Xue H; Yang B; Kristensen DD; Chen D
Hum Vaccin Immunother; 2014; 10(12):3607-10. PubMed ID: 25668668
[TBL] [Abstract][Full Text] [Related]
3. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a thermostable hepatitis B vaccine formulation.
Braun LJ; Jezek J; Peterson S; Tyagi A; Perkins S; Sylvester D; Guy M; Lal M; Priddy S; Plzak H; Kristensen D; Chen D
Vaccine; 2009 Jul; 27(34):4609-14. PubMed ID: 19523912
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.
Nelson CM; Wibisono H; Purwanto H; Mansyur I; Moniaga V; Widjaya A
Bull World Health Organ; 2004 Feb; 82(2):99-105. PubMed ID: 15042231
[TBL] [Abstract][Full Text] [Related]
6. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Propylene Glycol-Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging.
Mensch CD; Davis HB; Blue JT
PDA J Pharm Sci Technol; 2015; 69(4):477-98. PubMed ID: 26242785
[TBL] [Abstract][Full Text] [Related]
8. Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.
Hassett KJ; Vance DJ; Jain NK; Sahni N; Rabia LA; Cousins MC; Joshi S; Volkin DB; Middaugh CR; Mantis NJ; Carpenter JF; Randolph TW
J Pharm Sci; 2015 Feb; 104(2):627-39. PubMed ID: 25581103
[TBL] [Abstract][Full Text] [Related]
9. Exposure to heat and freezing in the vaccine cold chain in Thailand.
Techathawat S; Varinsathien P; Rasdjarmrearnsook A; Tharmaphornpilas P
Vaccine; 2007 Jan; 25(7):1328-33. PubMed ID: 17157419
[TBL] [Abstract][Full Text] [Related]
10. Stability of yellow fever vaccine.
Monath TP
Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the freeze sensitivity of a hepatitis B vaccine.
Chen D; Tyagi A; Carpenter J; Perkins S; Sylvester D; Guy M; Kristensen DD; Braun LJ
Hum Vaccin; 2009; 5(1):26-32. PubMed ID: 18971625
[TBL] [Abstract][Full Text] [Related]
12. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars.
Tonnis WF; Amorij JP; Vreeman MA; Frijlink HW; Kersten GF; Hinrichs WL
Eur J Pharm Sci; 2014 May; 55():36-45. PubMed ID: 24468629
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and challenges of developing thermostable vaccines.
Chen D; Kristensen D
Expert Rev Vaccines; 2009 May; 8(5):547-57. PubMed ID: 19397412
[TBL] [Abstract][Full Text] [Related]
14. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method.
Chen D; Kapre S; Goel A; Suresh K; Beri S; Hickling J; Jensen J; Lal M; Preaud JM; Laforce M; Kristensen D
Vaccine; 2010 Jul; 28(31):5093-9. PubMed ID: 20478345
[TBL] [Abstract][Full Text] [Related]
15. Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.
Fortpied J; Wauters F; Rochart C; Hermand P; Hoet B; Moniotte N; Vojtek I
Hum Vaccin Immunother; 2018 May; 14(5):1243-1250. PubMed ID: 29337646
[TBL] [Abstract][Full Text] [Related]
16. Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants.
Salnikova MS; Davis H; Mensch C; Celano L; Thiriot DS
J Pharm Sci; 2012 Mar; 101(3):1050-62. PubMed ID: 22113733
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cold chain monitoring in Kelantan, Malaysia.
Hanjeet K; Lye MS; Sinniah M; Schnur A
Bull World Health Organ; 1996; 74(4):391-7. PubMed ID: 8823961
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
Maa YF; Zhao L; Payne LG; Chen D
J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382
[TBL] [Abstract][Full Text] [Related]
19. Analysis of vaccine stability.
Volkin DB; Burke CJ; Sanyal G; Middaugh CR
Dev Biol Stand; 1996; 87():135-42. PubMed ID: 8854010
[TBL] [Abstract][Full Text] [Related]
20. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
